The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more.
Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners. Positive results could help win over large pharmaceutical companies and investors who have doubted microbiome therapies.
“In every new (drug) class there’s always been people… Read more »
UNDERWRITERS AND PARTNERS